Ortho Clinical Diagnostics Holdings Plc (OCDX)

They are a pure-play in vitro diagnostics (“IVD”) business driven by their credo, “Because Every Test is A Life.” This guiding principle reflects the crucial role diagnostics play in global health and guides their priorities as an organization. As a leader in IVD, they impact approximately 800,000 patients every day. They are dedicated to improving outcomes for these patients and saving lives through providing innovative and reliable diagnostic testing solutions to the clinical laboratory and transfusion medicine communities. Their global infrastructure and commercial reach allow them to serve these markets with significant scale. They have an intense focus on the customer. They support their customers with high quality diagnostic instrumentation, a broad test portfolio and market leading service. Their products deliver consistently fast, accurate and reliable results that allow clinicians to make better-informed treatment decisions. Their business model generates significant recurring revenues and strong cash flow streams from ongoing sales of high margin consumables. In 2019, these consumables contributed more than 90% of their total revenue and approximately 93% of their core revenue.

Industry
In Vitro & In Vivo Diagnostic Substances

CEO	CFO
Chris Smith	Joseph Busky

Chris Smith has been our Chief Executive Officer since September 2019 and he serves as a member of our board of directors. Mr. Smith was appointed Chairman in September 2020. From 2015 to 2018, Mr. Smith served as the Chief Executive Officer of Cochlear Limited. Prior to joining Cochlear Limited, he held senior executive roles at Gyrus Group Plc., KCI, Prism and Cardinal Health. Mr. Smith received a B.S. from Texas A&M University. Our board of directors has concluded that Mr. Smith should serve as a director because he brings extensive knowledge of the medical device industry within healthcare, which, together with his experience in leading the Company as our Chief Executive Officer, makes him well qualified to serve as one of our directors.

Joseph Busky has been our Chief Financial Officer since July 2020. Prior to joining Ortho, Busky served as chief financial officer for global medical device company, Vyaire Medical, Inc., from 2018 through 2020, as chief executive officer of Qualtek from 2017 to 2018, and as chief financial officer of FDH Velocitel from 2015 to 2017. He has also previously held leadership roles at InnerWorkings, Inc. and Siemens Medical Solutions Diagnostics/Dade Behring Holdings, Inc. Mr. Busky holds an MBA with a finance concentration, as well as a BBA in accounting, from Loyola University in Baltimore. He also holds a CPA certification in Maryland from the American Institute of Certified Public Accountants.

Employees	Founded
4500	1939

Address: 1001 Route 202 Raritan, New Jersey 08869

Telephone: 908-218-8000

Web page: http://www.orthoclinical.com

Expected Date	1/28/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the OCDX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: JP Morgan

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
JP Morgan/ BofA Securities/ Goldman Sachs/ Barclays/ Morgan Stanley/ Citigroup/ Credit Suisse/ UBS Investment Bank/ Evercore ISI/ Piper Sandler
CO-Managers
ING/ Macquarie Capital/ / Nomura/ TCG Capital Markets/ Drexel Hamilton/ H.C. Wainwright/ Ramirez & Co./ Siebert Williams Shank